Yüklüyor......
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
SIMPLE SUMMARY: Bruton tyrosine kinase (Btk) is expressed in B-lymphocytes, myeloid cells and platelets. Since the launch of the first in class Btk-inhibitor (BTKi) ibrutinib in 2013, the list of indications and further drug candidates has expanded greatly. BTKi are not only used to treat patients w...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7961939/ https://ncbi.nlm.nih.gov/pubmed/33806595 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051103 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|